Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;35(2):135-144.
doi: 10.1007/s40266-018-0520-z.

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Andreas Körber  1 , Charis Papavassilis  2 , Vaishali Bhosekar  3 , Maximilian Reinhardt  4
Affiliations

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Andreas Körber et al. Drugs Aging. 2018 Feb.

Abstract

Background: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis.

Aims: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects.

Methods: Studies were multicentre, randomized, parallel-group, double-blind, 52-week phase III trials in subjects with moderate to severe plaque psoriasis. For efficacy analyses, 67 elderly subjects (≥ 65 years) treated with secukinumab 300 mg were compared with 841 younger subjects (18-64 years). Psoriasis Area and Severity Index (PASI), Dermatological Life Quality Index (DLQI) and safety were analysed.

Results: Elderly subjects had higher baseline frequencies of cardiovascular and metabolic disorders. Secukinumab efficacy in elderly subjects was comparable to that in younger subjects throughout 52 weeks of treatment. PASI 75 response was reached by 81.8% of elderly subjects and 79.4% of younger subjects at Week 52. Similar rates of DLQI 0/1 response were observed. The total rate of adverse events was similar between elderly and younger subjects.

Conclusions: Secukinumab at the recommended dose (300 mg) is effective and acceptably safe in subjects aged ≥ 65 years with moderate to severe psoriasis, with quality-of-life benefits, despite an increased prevalence of cardiovascular and metabolic comorbidities in this population.

PubMed Disclaimer

Conflict of interest statement

Funding

The study was funded by Novartis Pharma GmbH, Germany.

Conflict of interest

AK has received honoraria from Novartis, Lilly, Leo Pharma, Almirall, Janssen, UCB, MSD and Pfizer and has received fees for board participation from Novartis, Leo Pharma, Janssen and Lilly. CP is an employee of Novartis Pharma AG. VB is an employee of Novartis Healthcare Pvt. Ltd. MR is an employee of Novartis Pharma GmbH.

Figures

Fig. 1
Fig. 1
Secukinumab efficacy in elderly and younger subjects in pooled studies. PASI and IGA mod 2011 0/1 response rates in the analysis population comprising patients treated with secukinumab 300 mg for up to 52 weeks in ERASURE, FIXTURE and CLEAR (non-responder imputation). PASI Psoriasis Area and Severity Index, DLQI Dermatological Life Quality Index, IGA mod 2011 0/1 modified Investigator’s Global Assessment
Fig. 2
Fig. 2
Absolute PASI scores at Week 52 in the analysis population comprising patients treated with secukinumab 300 mg for up to 52 weeks in ERASURE, FIXTURE and CLEAR. PASI Psoriasis Area and Severity Index, Q4 W every 4 weeks
Fig. 3
Fig. 3
DLQI response at Week 52 in the analysis population comprising patients treated with secukinumab 300 mg for up to 52 weeks in ERASURE, FIXTURE and CLEAR (last observation carried forward). DLQI Dermatological Life Quality Index
See this image and copyright information in PMC

References

    1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–ii23. - PMC - PubMed
    1. Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1):41–55. doi: 10.1016/j.det.2014.09.004. - DOI - PubMed
    1. Gan EY, Chong WS, Tey HL. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs Clin Immunother Biopharm. Gene Ther. 2013;27(4):359–373. - PubMed
    1. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895. - PMC - PubMed
    1. Phan C, Sigal ML, Esteve E, Reguiai Z, Barthelemy H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78–82. doi: 10.1111/jdv.12850. - DOI - PubMed

Publication types

LinkOut - more resources